Camurus Expands Share Capital After Employee Stock Option Exercises

The latest update is out from Camurus AB ( (SE:CAMX) ).

Camurus AB has increased its share capital following the exercise of 54,450 employee stock options under its ESOP 2022/2026 program, resulting in the issuance of an equal number of new registered shares. After this transaction, the total number of shares and votes in the company rose from 59,934,734 to 59,989,184 as of 31 March 2026, slightly diluting existing shareholders but reinforcing employee ownership and alignment with long-term company performance.

The change in capital structure is relatively modest in quantitative terms, yet it reflects continued utilization of equity-based incentives within Camurus’ workforce. Such option exercises are standard in growth-focused biopharmaceutical companies, supporting talent retention while incrementally expanding the free float and potentially enhancing share liquidity over time.

The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK513.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.

More about Camurus AB

Camurus AB is an international, science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for severe and chronic diseases. Using its proprietary FluidCrystal technology and R&D expertise, the company is advancing a pipeline targeting dependence, pain, cancer, and endocrine disorders, with operations across Europe, the U.S., and Australia and a listing on Nasdaq Stockholm under the ticker CAMX.

Average Trading Volume: 139,861

Technical Sentiment Signal: Sell

Current Market Cap: SEK26.97B

For an in-depth examination of CAMX stock, go to TipRanks’ Overview page.